R S Schulof
About
In The Last Decade
R S Schulof
14 papers receiving 476 citations
Peers
Comparison fields: 5 of 76
- Immunology 266
- Molecular Biology 111
- Oncology 82
- Virology 72
- Epidemiology 70
Countries citing papers authored by R S Schulof
This map shows the geographic impact of R S Schulof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R S Schulof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R S Schulof more than expected).
Fields of papers citing papers by R S Schulof
This network shows the impact of papers produced by R S Schulof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R S Schulof. The network helps show where R S Schulof may publish in the future.
Co-authorship network of co-authors of R S Schulof
This figure shows the co-authorship network connecting the top 25 collaborators of R S Schulof. A scholar is included among the top collaborators of R S Schulof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R S Schulof. R S Schulof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 63 | |
| 3 | Low-dose multidrug chemotherapy plus Pneumocystis carinii pneumonia prophylaxis for HIV-related Kaposi's sarcoma. | 6 |
| 4 | 2 | |
| 5 | 2 | |
| 6 | Effect of lithium carbonate in HIV-infected patients with immune dysfunction. | 22 |
| 7 | A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. | 28 |
| 8 | 19 | |
| 9 | 116 | |
| 10 | Phase I/II trial of thymosin fraction 5 and thymosin alpha one in HTLV-III seropositive subjects. | 6 |
| 11 | A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer. | 58 |
| 12 | Neuraminidase treatment of human T lymphocytes: effect on Fc receptor phenotype and function. | 10 |
| 13 | Thymosin and the endocrine thymus. | 6 |
| 14 | 203 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.